A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not adequately controlled by Somatostatin Analog (SSA) Therapy

Trial Profile

A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not adequately controlled by Somatostatin Analog (SSA) Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Telotristat etiprate (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TELESTAR
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 19 Sep 2017 According to an Ipsen media release, based on the results from TELESTAR and TELECAST studies the European Commission has approved Xermelo (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
    • 12 Sep 2017 Results of pooled analysis of 5 trials (NCT02026063, NCT02063659, NCT01677910, NCT01104415, NCT00853047) presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results of data from the full 48 weeks presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top